Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Asthma III: Clinical Manifestations

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

Antiasthma Drugs: Methylxanthines

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Prevalence of Sleep-Disordered Breathing in Children With Neuromuscular Diseases.

Cureus·2026

Same author

Adjunctive Mechanical Ventilation or Intravenous Hypertonic Saline in Malawian Children with Cerebral Malaria and Highly Increased Brain Volume: A Randomized, Phase 3 Clinical Trial.

Neurocritical care·2026

Same author

Development of the malay version of the patient satisfaction questionnaire for virtual consultation services (MPSQ-VC): content validity & face validity analysis.

BMC health services research·2026

Same author

Renal ultrasound after first febrile urinary tract infection in hospitalized children: The ROUTINE prospective observational study protocol.

Journal of hospital medicine·2026

Same author

Factors Associated With 72-Hour Emergency Department Revisits at a Tertiary Care Hospital in Saudi Arabia.

Cureus·2026

Same author

Economic evaluation of maternal healthcare services for Indigenous and rural people: a systematic review.

Rural and remote health·2026

Search research articles

Related Experiment Video

Updated: May 7, 2026

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

Oral dexamethasone for bronchiolitis: a randomized trial.

Khalid Alansari¹, Mahmoud Sakran, Bruce L Davidson

¹Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar. dkmaa@hotmail.com.

|September 18, 2013

Summary

This summary is machine-generated.

Dexamethasone added to salbutamol significantly reduced hospital stay for infants with bronchiolitis and asthma risk. This treatment shortened readiness for discharge by 31% without increasing readmissions or side effects.

Keywords:

bronchiolitis dexamethasone therapy length of stay respiratory infections respiratory syncytial virus

Related Experiment Videos

Last Updated: May 7, 2026

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

Area of Science:

Pediatric Pulmonology
Clinical Pharmacology

Background:

Bronchiolitis is a common viral respiratory infection in infants.
Asthma risk factors, such as eczema or family history, may influence bronchiolitis severity and treatment response.
Current treatment often involves supportive care and bronchodilators like salbutamol.

Purpose of the Study:

To evaluate the efficacy of dexamethasone combined with salbutamol in reducing hospital discharge time for infants with bronchiolitis and indicators of asthma risk.
To assess the safety and readmission rates associated with this combined treatment regimen.

Main Methods:

A randomized controlled trial comparing dexamethasone plus salbutamol to placebo plus salbutamol in infants with bronchiolitis and asthma risk factors (eczema or family history).
Dexamethasone dosage: 1 mg/kg followed by 0.6 mg/kg for 4 days.
Primary outcome: time to readiness for discharge. Secondary outcomes included intensive care unit admissions and 7-day readmission/adverse event rates.

Main Results:

Dexamethasone treatment resulted in a 31% shorter mean time to readiness for discharge (18.6 hours) compared to placebo (27.1 hours) (P = .015).
Five placebo recipients required intensive care unit admission, versus none in the dexamethasone group (P = .02).
Readmission rates and reported side effects were similar between the dexamethasone and placebo groups within the 7-day surveillance period.

Conclusions:

Dexamethasone, when added to salbutamol, effectively shortens the time to discharge for infants hospitalized with bronchiolitis who have a history of eczema or asthma.
The combined treatment demonstrates a favorable safety profile, with no significant increase in readmissions or adverse events compared to placebo.